AmgenvsHalozyme Therapeutics

AMGN and HALO stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$440.22

Value $237B

+0.32%
AMGN's page

HALO

Halozyme Therapeutics, Inc.

$92.73

Value $10.9B

-0.33%
HALO's page

Amgen (AMGN) has a market value of $237B and Halozyme Therapeutics (HALO) $10.9B. Over the last year, with dividends, AMGN moved +32.1% and HALO +32.0%. The P/E is 25.3 for AMGN and 22.6 for HALO. Dividend yield: AMGN 2.26%, HALO none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$237B

    HALO$10.9B

    AMGN is 22 times HALO

  • Revenue, 12 months

    AMGN$38.9B

    HALO$1.8B

    AMGN is 22 times HALO

  • Net income, 12 months

    AMGN$9.4B

    HALO$485M

    AMGN is 19 times HALO

  • Operating margin

    AMGN32.4%

    HALO37.4%

    5.0 points apart

  • ROIC

    AMGN16.2%

    HALO20.7%

    4.5 points apart

  • P/E

    AMGN25.3

    HALO22.6

    AMGN is 1.1 times HALO

  • Dividend yield

    AMGN2.3%

    HALO0.0%

    2.3 points apart

  • 5-year return

    AMGN+147.5%

    HALO+161.0%

    13.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+147.5%

HALO+161.0%

10020030020222023202420252026
Returns by period
PeriodAMGNWith dividendsHALOWith dividends
1 year since November 19, 2025+32.1%Price +28.6%+32.0%Price +32.0%
3 years since November 20, 2023+80.1%+21.7% a yearPrice +65.9%+131.8%+32.3% a yearPrice +131.8%
5 years since November 19, 2021+147.5%+19.9% a yearPrice +113.6%+161.0%+21.2% a yearPrice +161.0%
10 years since November 21, 2016+304.6%+15.0% a yearPrice +202.5%+633.7%+22.1% a yearPrice +633.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenHALOHalozyme Therapeutics

Valuation

AMGNHALO
Valuation
Price$440.22$92.73
Market value$237B$10.9B
Enterprise value (EV)$278B$13.1B
P/E25.322.6
P/E, 5-year median23.017.6
P/B16.5–
EV/EBIT22.119.5
Free cash flow yield4.0%8.1%

Results and growth

AMGNHALO
Results and growth
Revenue, 12 months$38.9B$1.8B
Net income, 12 months$9.4B$485M
Free cash flow, 12 months$9.6B$886M
Earnings per share, 12 months$17.25$4.01
Revenue growth, year on year10.0%37.6%
Revenue growth a year, past+7.6%over 5 years+39.2%over 5 years
EPS growth a year, past+2.9%over 5 years+23.0%over 5 years

Margins and returns on capital

AMGNHALO
Margins and returns on capital
Gross margin70.9%82.3%
Operating margin32.4%37.4%
Net margin24.1%26.9%
ROIC16.2%20.7%
ROE87.8%282.0%

Balance sheet

AMGNHALO
Balance sheet
Cash$13.2B$1.1B
Total debt$54.0B$3.3B
Net debt / EBITDA2.33.2
Interest cover4.8×30.6×

Dividends and buybacks

AMGNHALO
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield–3.1%
Shareholder yield2.3%3.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or HALO

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Halozyme Therapeutics?

By market value, Amgen ($237B) is about 21.7 times Halozyme Therapeutics ($10.9B), at today's prices.

How did AMGN and HALO stock do over the last 10 years?

Since November 21, 2016, AMGN's price moved +202.5% and HALO's +633.7%. With dividends: AMGN +304.6% (+15.0% a year), HALO +633.7% (+22.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or HALO?

The dividend yield at today's price is 2.26% for Amgen and none for Halozyme Therapeutics. Over the last twelve months they paid $9.94 and – per share.

What is the P/E of AMGN and HALO?

At today's price, the P/E is 25.3 for AMGN and 22.6 for HALO. The median of the last five years was 23.0 and 17.6, which shows where each stands against its own past.

Which has the higher profit margins, Amgen or Halozyme Therapeutics?

Over the last twelve months, the net margin was 24.1% for Amgen and 26.9% for Halozyme Therapeutics, and the operating margin 32.4% and 37.4%. Revenue was $38.9B and $1.8B.

Which is the better investment, Amgen or Halozyme Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.